Pradaxa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and eighty-seven patent family members in fifty-one countries.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
Summary for PRADAXA
|Suppliers / Packagers:||2|
|Bulk Api Vendors:||52|
|Formulation / Manufacturing:||see details|
|Drug Prices:||see details|
|DailyMed Link:||PRADAXA at DailyMed|
Continue at: https://www.drugpatentwatch.com/p/tradename/PRADAXA
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link